Prellis Biologics Stock

prellisbio.comHealthcareFounded: 2016

Prellis Biologics, is a San francisco, California based 3-D printing company specializing in organ and tissue engineering. Prellis Biologics focuses on research and development that aims to provide solutions within the transplatation and donation healthcare industry, through holographic bioprinting. Additionally, Prellis Biologics researches healthcare solutions for cancerous diseases such as tumor, through its proprietary, 3-D technology.

Register for Details

For more details on financing and valuation for Prellis Biologics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Prellis Biologics.

Register Today

Team

Management Team

Mike Nohaile
Chief Executive Officer
Melanie Matheu, PhD
Founder & Chief Technology Officer
kevin Chapman, PhD
Chief Scientific Officer
Yelda Kaya, MBBS, LLC, MBA
Chief Business Officer
Andrew McFarland, PhD
Senior Vice President of Technology
Erin Stephens, PhD
Vice President of Tissue Engineering and Antibody Discovery

Board Members

James Rothman
Cell Biologist
Lei Meng
Advisor
Michael Marks
Celesta Capital

Other companies like Prellis Biologics in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$4.26B
Sector
Last Round Est. Valuation
$317.32MM
Sector
 
 
Sector
Last Round Est. Valuation
$1.59B
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$334.19MM

News

Prellis Biologics, a San Francisco, CA-based biotherapeutics company, raised $35M in Series C funding